Research chemicalPsychedelicTryptamine4-substituted tryptamine

4-HO-DSB

Also known as 4-hydroxy-N,N-disubstituted tryptamine

Written by enwyReviewed 5 Aug 20261 sources0 comments

4-HO-DSB is an obscure 4-hydroxy N,N-disubstituted tryptamine in the psilocin family. It is a research-chemical tryptamine with essentially no reliable human data and is included as a family reference for novel 4-substituted tryptamines.

01 Overview

4-HO-DSB belongs to the psilocin-like 4-hydroxytryptamine group, where varying the N-alkyl substituents modulates potency, duration and character. Like most rare members of this family, it has appeared only sporadically and lacks any structured human characterisation.

Effects, if the compound is active, would be expected to resemble other 4-HO tryptamines: shorter than psilocybin with variable visual and emotional components. This is inference, not observation.

02 Mechanism

Presumed 5-HT2A partial agonist like other 4-hydroxytryptamines; the free 4-hydroxyl aids central activity without requiring dephosphorylation.

03 Dosing

Tier	Dose	Route	Notes
Estimated	10–30 mg	Oral	Extrapolated from related 4-HO tryptamines; not established.

04 Effects

Effect	Magnitude	Evidence
Presumed visual psychedeliaInferred psilocin-like visual/emotional effects; not directly reported.	uncertain	Unconfirmed
Mood alterationVariable emotional shift expected by analogy to related tryptamines.	uncertain	Unconfirmed

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
NauseaOnset nausea common to 4-HO tryptamines; expected here.	Mild	Unknown	Unconfirmed
Unknown potency and toxicityNo dose-response or safety data exist; active dose is uncertain.	Moderate	Unknown	Unconfirmed

06 Legal status

United Kingdom

Psychoactive Substances Act 2016

as of Jan 2026

United States

Not specifically scheduled

May be an analogue of psilocin under the Federal Analogue Act if intended for consumption. · as of Jan 2026

07 References

Pharmacology of 4-substituted tryptamine psychedelics (review)Klein et al., ACS Chem Neurosci, 2021

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.